An Ionis Pharmaceuticals drug has preliminary data showing it met the main goal of its pivotal test in a rare disease with only a handful of approved treatments. With these results in hand, Ionis is ...

Jonathan Wosen is STAT’s West Coast biotech & life sciences reporter. You can reach Jonathan on Signal at jwosen.27. Ionis Pharmaceuticals won approval from the Food and Drug Administration on ...

Ionis Pharmaceuticals IONS signed a license agreement with Japan-based Ono Pharmaceutical. Per the terms, Ono has acquired exclusive global rights from IONS to develop and market sapablursen, an ...

FILE PHOTO: Illustration shows a test tube in front of displayed Biogen logo (Reuters) - Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental ...

Roche is paying $55 million for the rights to the Ionis drug, IONIS-FB-LRx. IgAN stems from the buildup in the kidney of a protein called immunoglobulin A. The disorder leads to kidney inflammation.

Shares of Ionis Pharmaceuticals IONS rose nearly 5% in after-market trading on Thursday after the FDA approved its RNA-targeted therapy, olezarsen, in adults with familial chylomicronemia syndrome ...

Ionis Pharmaceuticals, a California company that pioneered a whole class of RNA-targeted medicines, reported on Friday that a pair of late-stage trials showed that its experimental therapy for ...

CARLSBAD, Calif.--(BUSINESS WIRE)-- Ionis Pharmaceuticals, Inc. (IONS) (Nasdaq: IONS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for Priority Review the New Drug ...

Jan 22 (Reuters) - Ionis Pharmaceuticals (IONS.O), opens new tab said on Monday its experimental drug reduced the occurrence of painful attacks in patients with a rare genetic disease that triggers ...

(Reuters) - Biogen and Ionis Pharmaceuticals said on Thursday they will terminate the development of their experimental treatment for amyotrophic lateral sclerosis (ALS) after failing to show ...